This Medical Device Alert has been issued due to component failures, which affect AC (mains) and/or DC (battery) operating power, there is a risk that the defibrillator will not deliver therapy.

Holders of authorisations, registrations and licences are required to notify the MHRA by 31 December 2010 to cancel authorisations, registrations and licences from 31 March 2011.

A 61-year-old man from Sutton Coldfield, West Midlands, received a nine-month prison sentence suspended for two years yesterday (Monday 6 September), with supervision for one year, at Birmingham Crown Court for the illegal sale and supply of erectile dysfunction medicines.

This Medical Device Alert has been issued because the manufacturer, DuPuy International Ltd, has recalled ASR™ hip replacement implants due to increased rates of revision.

This Medical Device Alert has been issued as an incident has been reported where a patient suffered a stroke when an IV extension set, which had a vented cap attached to its Y-port, was connected to a central line.

The MHRA is contributing to the ongoing Europe wide review of rosiglitazone.

A list of letters sent to healthcare professionals in August 2010, to inform of new safety information and advice.

We have received encouraging results of UK testing on the silicone gel breast implants manufactured by the French company Poly Implant Prosthese (PIP). The tests found no evidence of genotoxicity (potential for cancer) or chemical toxicity of the filler material in the implants.

In draft guidance published today (10 September 2010), NICE recommends liraglutide (Victoza, Novo Nordisk) 1.2 mg daily for some people with type 2 diabetes mellitus. However, it does not recommend liraglutide at 1.8mg daily, as the available evidence does not suggest any significant additional benefit with the higher dose.

In draft guidance, published today (10 September 2010), NICE has asked Bristol-Myers Squibb and Otsuka Pharmaceuticals to provide more data on the effectiveness of their product, aripiprazole (Abilify), as a treatment for schizophrenia in people aged 15 to 17 years.

Heart of Mersey is hosting an event at the end of September to highlight NICE's guidance on how to prevent cardiovascular disease (CVD). The guidance focuses on the food we eat and confirms the need for a 'population-level' approach.

In draft guidance published today (26 August 2010) NICE has recommended two treatments for multiple myeloma.

NICE's final guidance on dronedarone recommends the use of the drug as a second-line treatment in people with additional cardiovascular risk factors whose atrial fibrillation (AF) has not been controlled by first-line therapy (usually including beta-blockers).